Business Wire

EFFISSIMO-CAPITAL-MGMT

Share
Effissimo Releases Presentation Explaining Proposal to Appoint Independent Investigators at Toshiba

Effissimo Capital Management (“Effissimo”), the largest shareholder of Toshiba Corporation (“Toshiba”) (TYO:6502) through the funds it manages, today released a presentation explaining the reasons behind its proposal for an independent investigation into reported irregularities surrounding Toshiba’s July 2020 Annual General Meeting of Shareholders (“AGM”). Effissimo’s proposal will be voted on by Toshiba’s shareholders at an extraordinary shareholders meeting scheduled for March 18, 2021.

The full proposal in English can be found here .

Supplementing its letter to shareholders dated February 24, 2021, Effissimo’s presentation explains its proposal for an independent investigation into the irregular handling of shareholder voting and shareholder pressure at the closely contested AGM, which Toshiba’s conflicted Audit Committee’s self-audit fails to address.

The presentation provides data showing discrepancies in the claimed delivery times of mailed ballots said by Toshiba’s vote tabulator to have been delivered past the AGM deadline and not counted. It also examines the artificially limited scope and conclusions of Toshiba’s Audit Committee’s investigations into shareholder pressure and vote tampering allegations.

Finally, the presentation provides a detailed historical context of chronic governance and oversight dysfunction at Toshiba that has persisted despite the installation of new management in 2017.

Vote Delivery & Tabulation

  • Inexplicable Delay in Ballot Delivery: Effissimo’s own field tests and review of other Japanese companies’ AGMs confirm Japan Post, in accordance with its own service guidelines, normally takes at most three days to deliver domestic mail. But Toshiba’s vote tabulator insists that it took four days, in breach of Postal Law, for ballots to be delivered.
  • Uncounted Ballots: There are still nearly 1,000—but possibly more than 1,600—additionally reported ballots that have yet to be audited by the Audit Committee due to claims they were delivered too late to be counted. These ballots should have ordinarily arrived prior to the vote deadline, absent the inexplicable delay in ballot delivery.
  • Treatment of Blank Ballots: Mailed ballots made up more than one-third of Toshiba’s quorum at the AGM – a substantial portion of shareholder participation. Roughly 17% of ballots were blank, which Toshiba treated as favorable to management. While lawful, this is clearly an anti-dissident practice that Toshiba could have abandoned after a shareholder proposal in this regard back in 2015.

Shareholder Pressure

  • Decline in Shareholder Participation: In a closely contested vote that attracted intense interest and attention, participation at the AGM declined by three percentage points year-over-year, providing grounds for suspicion that voter suppression in fact occurred.
  • Multiple Institutional Investors Absent from AGM: Credible media outlets have reported that shareholders were “pressured” and/or “threatened” with a probe if they voted against Toshiba management. Toshiba’s voting records indicate that some institutional shareholders that normally vote as a matter of course did not vote at the AGM. Effissimo’s confidential survey confirmed that multiple shareholders were pressured.

Although it may appear complex, the heart of issue is simple. Effissimo believes there should be an independent investigation as opposed to a self-audit by a conflicted Audit Committee.

The Audit Committee, chaired by a director whose reappointment was opposed by more than 40 percent of shareholders at the AGM, is conflicted and is naturally reticent to conduct an uninhibited investigation of possible wrongdoing at the AGM. This conflict manifests itself in the Audit Committee’s reviews and investigations, which we suspect are deliberately limited in scope at the outset to produce a pre-determined result.

The right to vote is what is at stake. Shareholders must not passively accept the Board’s explanations at face value and allow the status quo of weak governance to persist. Failure to perform a thorough and independent investigation will set a harmful precedent not only for Toshiba but also for corporate Japan as a whole.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye